Background: Campylobacter jejuni causes diarrhea worldwide; young children are most susceptible. Binding of virulent C. jejuni
Introduction
Campylobacter jejuni is the leading cause of enteric bacterial infection worldwide and poses a substantial challenge to public health (1), especially for young children. Domestic fowl serve as a reservoir for human infection, with further transmission through contaminated food, water, and direct fecal-oral contact. C. jejuni infection causes local acute inflammatory changes in both the small and large bowel (2) . After an incubation period of ;24-72 h, C. jejuni infection typically causes cramping and abdominal pain and is often associated with fever, vomiting, and headache (3) . The subsequent diarrhea can vary from a mild, noninflammatory, watery presentation to one that is severe and bloody (4) and generally lasts for ;7 d in otherwise healthy, immunocompetent individuals. After a C. jejuni infection resolves, there remains a residual elevated risk of severe complications, including GuillainBarré syndrome and irritable bowel syndrome (5) .
Virulence factors and mechanisms of C. jejuni infection are being actively investigated. A wide array of surface glycans of C. jejuni allow evasion of host defenses and resistance to proteolytic degradation (6) . C. jejuni-infected ferrets (7) reflect human infection well, but this expensive model lacks a full complement of reagents to define the host response to infection. In C. jejuniinoculated mice, the host response of the intestinal mucosa is inconsistent (8) (9) (10) (11) , suggesting that variation in murine microbial colonization could influence the transition from C. jejuni colonization to C. jejuni infection. Taking this into account, mice were treated with a cocktail of antibiotics for 6-8 wk before inoculation with C. jejuni. Antibiotic treatment allows murine C. jejuni infection, but the high counts of C. jejuni in the stomach and proximal intestine are not typical of human infection (12) . Another study compared wild-type and Sigirr 2/2 [Sigirr protein is a negative regulator of toll-like receptor 4 (TLR4) 6 signaling] knockout mice that had been inoculated with C. jejuni 4 h after vancomycin gavage; wild-type mice showed minimal pathology, indicating that this treatment does not closely model human infection (13) . To allow testing of potential therapeutic agents in the context of an intact appropriate host mucosal immune response, we developed a model of antibiotic-treated wild-type mice that become susceptible to infection by a clinical isolate of C. jejuni. In this model, the antibiotics per se did not elicit an inflammatory response, and the shift in microbiota allowed C. jejuni infection that closely recapitulated the pathobiology of human disease with regard to time course, inflammatory response, and spontaneous clearance of mucosal and systemic infection.
Human milk oligosaccharides (HMOSs) are putative protective agents against enteric infection (14) . Oligosaccharides, the third-largest fraction of human milk, consist of thousands of components and, in most mothers, are predominantly fucosylated. C. jejuni binds diverse host glycans, including fucosylated glycans, that are crucial for the initial attachment to and continued colonization of the host (14, 15) . Fucose binding is a critical determinant of C. jejuni pathogenesis and is strongly inhibited by HMOSs and by 2#-fucosyllactose (2#-FL), a major constituent of the HMOSs (10) . The ability of 2#-FL to inhibit C. jejuni binding is consistent with the inverse relation between concentrations of 2-linked fucosyl oligosaccharides in milk consumed by infants and the risk of C. jejuni-caused moderate-tosevere diarrhea in a prospective study in breastfeeding motherinfant dyads (16, 17) . Prebiotic activity of oligosaccharides also may be protective (18, 19) ; these indigestible glycans provide a carbon source for mutualistic bacteria that promote the colonization of the gut by a protective community of microbes.
Elucidating the molecular mechanisms whereby C. jejuni pathobiology could be inhibited by HMOSs (20) requires an appropriate model. In mice, reducing the gut microbial diversity by using a specific cocktail of antibiotics before inoculation allows Salmonella typhimurium, Clostridium difficile, and Shigella dysenteriae to infect with pathology that recapitulates human disease: inflammation is followed by spontaneous clearance of the infection after several weeks (21, 22 ). This strategy was tested for its ability to allow infection by C. jejuni and was modified to accommodate specifics of C. jejuni pathobiology.
A study was designed to test whether HMOSs inhibit infection and its sequelae by a clinical isolate of C. jejuni and whether pure 2#-FL can account for this activity. First, cell culture models of human epithelium, HEp-2, and of human intestinal epithelium, HT-29, were used to test the ability of synthetic 2#-FL to inhibit C. jejuni infection. When 2#-FL proved to be effective, a novel murine C. jejuni model that exhibited typical acute transient enteric infection, immune response, and spontaneous clearing was developed and used to test the hypothesis that a single HMOS, 2#-FL, could inhibit C. jejuni infection of the intestinal epithelium and C. jejuni-associated mucosal inflammation.
Methods
HMOSs. HMOSs were prepared from pooled human milk as described previously (16) . Pure 2#-FL was produced by microbial fermentation and brought to >99% purity by Glycosyn LLC.
Bacterial strains. C. jejuni strain 81-176 (a kind gift by Patricia Guerry, Naval Medical Research Center, Maryland) was cultured through one passage on trypticase soy agar plates containing 5% sheepÕs blood (BD) for 2 d under microaerophilic conditions at 37°C.
Intestinal epithelial cells. The effects of C. jejuni infection are not robust in many common cell lines (23) . Thus, the human epithelial cells (HECs) HEp-2 (cervical origin) and HT-29 (intestinal origin) were cultured as polarized epithelial cell monolayers to model C. jejuni infection and its inhibition. HEp-2 cells were grown in MEM and HT-29 were grown in McCoyÕs medium, each supplemented with 10% FBS (Gibco), without antibiotics, in 75-cm 2 flasks (Falcon) at 37°C in a 5% CO 2 humidified atmosphere. Trypsinized HEp-2 or HT-29 cells were seeded (5.0 3 10 4 in 1 mL) in 6-well tissue culture plates. After 18 h of incubation, the semiconfluent monolayers were washed and incubated with MEM containing 1% FBS; confluent monolayers were used for the invasion study. Invasion was measured by staining with fluorescein isothiocyanate-labeled C. jejuni, with nuclei stained with 4#,6-diamidino-2-phenyindole dihydrochloride. Inflammatory response to infection was determined by measuring IL-8, IL-1b, macrophageinflammatory protein 2 (MIP-2), and TNF-a, as well as levels of their corresponding mRNA.
Invasion assay. In Expt. 1, binding by C. jejuni or heat-killed C. jejuni to HEp-2 or HT-29 HECs was assessed as described previously (10, 24) . C. jejuni (1 3 10 8 CFUs/mL) alone or previously treated for 1 h with 2 g 2#-FL/L, Ulex europaeus agglutinin I (UEA-I) lectin (positive control), Lotus tetragonolobus lectin, L-fucose, or Dolichos biflorus agglutinin (negative control; EY Laboratories) were inoculated into wells containing HEp-2 or HT-29 cells. The cells were incubated for 2 h followed by the removal of extracellular C. jejuni by using 100 mg gentamicin/L (Sigma) as described previously (10, 24) . C. jejuni colonies formed by plated epithelial cell lysates, with 4 replicate wells/Expt. in 3 independent Expts. were analyzed as 3 independent measurements.
In Expt. 2, the dose response of 2#-FL inhibition of invasion was likewise assessed over the range that can be found in human milk, from a high of 5 g/L, through the median value of 2 g/L, through low values of 1 and 0.5 g/L, and to 0 g/L. The lowest values represent milk of nonsecretors who are homozygous recessive for the FUT2 gene and do not secrete a 1,2 -linked fucosylated epitopes in their exocrine secretions, including milk.
Bacterial infection of mice. A C57BL/6 murine model was developed to minimize variable microbiota effects on C. jejuni infection (Boston College Institutional Animal Care and Use Committee protocol 2011010). Fourweek-old C57BL/6 male mice (Jackson Laboratories) were housed with a 12-h light-dark cycle and had access to a standard unpurified mouse diet (Prolab RMH 3000, 5P00; LabDiet) and water ad libitum. LabDiet 5P00 contains ;22% protein, ;5% fat, and ;5% crude fiber.
Expt. 3 tested conditions that promoted C. jejuni infection of mice. Groups of 4 mice were treated for 1, 3, or 7 d with an antibiotic cocktail in drinking water to disrupt the microbiota (25) (10 8 CFUs/mouse) for 1, 3, or 7 d. Mice were weighed and feces collected daily. Mice were killed 1 d after the final C. jejuni gavage, and tissues were collected. Body-weight data were normalized to the body weight of each mouse at the outset of the experiment (the day of initiation of antibiotic treatment) to isolate the variance in changes due to the experimental treatment from the initial variance in body weights. A 3 d inoculum was sufficient for full infection. The experimental murine model for C. jejuni infection was thus 7 d of antibiotic cocktail followed by 3 daily inocula of 10 8 CFUs/ mouse in 100 mL saline gavage.
Expt. 4 tested whether 2#-FL could inhibit C. jejuni infection and inflammatory response. The 5 arms each consisted of groups of four 4-wk-old C57BL/6 mice pretreated with the antibiotic cocktail, as follows: 1) uninfected negative controls, 2) uninfected mice administered 5 g 2#-FL/L in their water for 3 d, 3) mice infected with C. jejuni with no further intervention (positive controls), 4) mice infected with an inoculum of C. jejuni that also contained 2#-FL, and 5) mice administered 5 g 2#-FL/L in their drinking water for 3 d before and concurrent with the inoculum, which, as in group 4, contained both C. jejuni and 2#-FL.
This combined inoculum does not affect C. jejuni viability per se (10), and 5 g 2#-FL/L in drinking water recapitulates the upper range of its concentrations in human milk. Mice were examined daily and weighed, and the presence and severity of rectal bleeding were recorded. On alternate days, fresh fecal samples were collected and stored at 220°C. The disease activity index (DAI) is a composite of weight loss, bleeding, and diarrhea symptoms (26) . Scoring was performed by researchers blinded to the experimental status (e.g., 2#-FL, C. jejuni treatment) of the mice.
C. jejuni infection. C. jejuni was quantified in fecal samples obtained from the colon after mice were killed. Log dilutions of 100 mL feces in 9 volumes of PBS were plated in duplicate on C. jejuni -selective agar (Oxoid; 48 h, 37°C microaerophilic). C. jejuni was also quantified in feces and tissues by real-time PCR with the use of C. jejuni-specific primers VS15 and VS16 from VS1 sequence (X71603), as described previously (27) .
Tissue collection. Isoflurane-anesthetized mice were killed by cervical dislocation. Proximal and distal segments of colons were cleaned with ice-cold PBS, spleen and mesenteric lymph nodes (MLNs) were frozen immediately in liquid nitrogen for isolation of total RNA. Other colonic tissues fixed in 4% buffered paraformaldehyde for 12 h at 4°C were imbedded in paraffin, and 8-mm sections were stained with hematoxylin and eosin. Colonic tissue segments washed in PBS containing penicillin and streptomycin were cut into 5 3 5 mm 2 explants for culture.
Histology, pathologic scoring. Bowel tissues fixed in 10% formalin, paraffin embedded, cut for histologic analysis, and stained with hematoxylin and eosin were subjected to pathologic scoring by 3 blinded observers (13, 28) .
Immunohistochemistry. In situ immunohistochemical analysis was performed on the colonic paraffin sections by using primary antibodies against CD3 (dilution of 1:100; Abcam) and myeloperoxidase-7 (dilution of 1:100; Abcam). For each mouse, the mean number of positively stained cells within $6 high-power fields (4003 magnification) was determined microscopically by 3 independent investigators.
Cytokines and chemokines. The mucosal immune response to infection was determined by measuring selected NF-kB-dependent inflammatory mediators in the colon, the primary site of C. jejuni infection. IL-6 and TNF-a induction represented overall acute inflammatory response, MIP-2 induction exemplified the degree of expression of a neutrophil chemoattractant, IL-1b induction represented the degree of activation of inflammasome, and IL-17 induction reflected the degree of polarization of the T-helper cells in response to infection as a measure of adaptive immune response. Proximal and distal colon segments were cultured in 24-well flatbottom culture plates (Falcon) containing serum-free DMEM (Gibco) with penicillin (100 U/L) and streptomycin (100 U/mL) (29) . The media were collected after 20 h, centrifuged, frozen, and stored at 220°C, as described (20) . IL-1b, IL-6, TNF-a, MIP-2, and IL-17 concentrations were measured by ELISA (R&D Systems).
The relative inhibition of the activation of phosphorylated protein 38 (p-p38) by 2#-FL and by SB203580 (10 mM; Cell Signaling Technology), an inhibitor of protein 38 (p38) MAPK, was compared in C. jejuniinfected HT-29 cells and C57BL/6 mouse colon. Values were normalized to total mucosal protein, as assessed by the bicinchoninic acid assay (BCA kit, Pierce-ThermoFisher).
Cytokine and chemokine mRNA. RNA from tissue homogenates (RNeasy Mini Kit; Qiagen) generated cDNA by using random hexamers (GeneAmp RNA PCR Kit; Applied Biosystems). Inflammatory cytokine and chemokine mRNAs were quantified by RT-PCR. Primer sequences (30) (31) (32) are shown in Supplemental Table 1 .
Statistical analysis.
Results from each in vitro experiment are from 3 independent Expts. (each the mean of 4 wells) and are expressed as means 6 SDs. Treatment effects were analyzed in Supplemental Figure  1 by single-tailed StudentÕs t test. Experimental results in Figure 2 and Supplemental Figure 2 , which were normally distributed, homogeneous, and composed of independent data with only 1 independent variable, were analyzed by Bonferroni-corrected 1-factor ANOVA; if the ANOVA produced P < 0.05, a post hoc TukeyÕs honestly significant difference test determined the significance of individual group comparisons. Data from experiments with 2 independent variables, C. jejuni infection and 2#-FL treatment, after testing for homoscedasticity by LeveneÕs median test, were analyzed by 2-factor ANOVA (C. jejuni infection 3 2#-FL treatment) followed by mean comparisons with Bonferroni adjustment. Results are expressed as means 6 SDs. P # 0.05 was considered significant. In Figure 1B , decreases in infection as a function of 2#-FL concentration were analyzed by generating best-fit regression curves, from which R and P for the closeness of fit were calculated (Microsoft Excel for MAC, version 14.5.4).
Results
C. jejuni infection in vitro. Infection of HEp-2 or HT-29 cells with fluorescein isothiocyanate-labeled C. jejuni was measured as number of C. jejuni per cell. Expt. 1 indicated that the infection was similar for both HEp-2 and HT-29 epithelial cells (Supplemental Figure 1) . Expt. 1 also indicated that C. jejuni infection was inhibited by 2 g HMOSs/L, 2#-FL or UEA-I, in both HEp-2 and HT-29 cells (P < 0.05) but was not affected by Dolichos biflorus agglutinin, L-fucose, or Lotus tetragonolobus lectin treatment ( Figure 1A ).
Expt. 2 determined that the inhibition of C. jejuni infection was dose dependent in both HEp-2 (P = 0.01 for closeness of fit to curve) and HT-29 (P = 0.02) cells ( Figure 1B) . The halfmaximum inhibitory concentration of 2#-FL is ;1 g/L for both cell types; typical secretor human milk contains 2-3 g/L. Thus, the inhibition by 2#-FL alone can account for the complete inhibition of C. jejuni infection by concentrations of HMOSs that represent human milk. Inhibition by 2#-FL is mediated by attenuating pathogen-induced p38 activation in the epithelial cells (Supplemental Figure 3A) .
In HEp-2 cells, C. jejuni infection induced the expression of IL-8 (P < 0.0005), IL-1b (P < 0.0005), MIP-2 (P = 0.001), and TNF-a (P < 0.0005) ( Figure 1C ) and the corresponding expression of chemokine (C-X-C motif) ligand 8 (gene for IL-8) (CXCL8) mRNA (P = 0.001), IL1B mRNA (P = 0.003), CXCL2 mRNA (P < 0.0005), and tumor necrosis factor a (TNFA) mRNA (P < 0.0005) ( Figure 1D ). Two-factor ANOVA indicated a significant interaction between 2#-FL treatment and C. jejuni infection of HEp-2 cells for the induction of protein expression of IL-8, IL-1b, MIP-2, and TNF-a ( Figure 1C ) and their respective CXCL8, IL1B, CXCL2, and TNFA mRNAs (P-interaction < 0.0005 for all) ( Figure 1D ). Mean comparisons with Bonferroni adjustment indicated significant attenuation by 2#-FL of C. jejuni induction of proteins IL-8 by 64% (P < 0.0005), IL-1b by 86% (P < 0.0005), MIP-2 by 36% (P < 0.0005), and TNF-a by 12% (P = 0.006) ( Figure 1C ). Treatment with 2#-FL reduced CXCL8 mRNA expression by 42% (P < 0.0005), IL1B mRNA expression by 64% (P < 0.0005), CXCL2 mRNA by 28% (P = 0.006), and TNFA mRNA by 19% (P < 0.0005) ( Figure 1D ).
In HT-29 cells, C. jejuni infection induced IL-8, IL-1b, MIP-2, and TNF-a ( Figure 1C ) and the corresponding expressions of CXCL8 mRNA, IL1B mRNA, CXCL2 mRNA, and TNFA mRNA (P < 0.0005 for all) ( Figure 1D ). Two-factor ANOVA indicated a significant interaction between 2#-FL treatment and C. jejuni infection of HT-29 cells for the induction of protein expression of IL-8, IL-1b, MIP-2, and TNF-a (P-interaction < 0.0005 for all) ( Figure 1C ) and their respective CXCL8, IL1B, CXCL2, and TNFA mRNAs (P-interaction < 0.0005 for all) ( Figure 1D ). Mean comparisons with Bonferroni adjustment indicated significant attenuation by 2#-FL of C. jejuni induction of protein expression in HT-29 cells for IL-8 by 66%, IL-1b by 90%, MIP-2 by 50%, and TNF-a by 57% (P < 0.0005 for all) ( Figure 1C ). Treatment with 2#-FL reduced the corresponding CXCL8 mRNA expression by 64%, IL1B mRNA expression by 50%, CXCL2 mRNA by 61%, and TNFA mRNA by 41% (P < 0.0005 for all) ( Figure 1D ). The inability of heat-killed C. jejuni to elicit elevated expression of the above inflammatory mediators indicates that these responses are mediated by C. jejuni infection per se rather than by an epithelial response to bacterial binding or activation of innate immune receptors by LPS or other microbial pattern molecules.
C. jejuni infection in vitro. Oral inoculation of conventional specific pathogen-free mice with clinical isolates of human pathogens often does not result in the infection and sequelae of human disease, but disruption of the murine microbiota by antibiotic treatment can render mice susceptible. A minimum antibiotic treatment appropriate for infecting mice with a clinical human isolate of pathogenic C. jejuni was determined empirically (Supplemental Figure 2 ). Expt. 3 tested various permutations of timing and duration of an antibiotic cocktail in drinking water before C. jejuni inoculation that would allow the most appropriate infection. Seven days of antibiotic treatment produced greater C. jejuni colonization than treatment for 1 or 3 d, with sequelae resembling human infection. One-factor ANOVA of decrements in body weight (time 0 = 100% for each individual mouse) after inoculation that followed variable antibiotic treatments indicated a significant effect of duration (P < 0.0005). Subsequent TukeyÕs honestly significant difference test indicated that the 3-and 7-d antibiotic treatment group body weights differed from one another and from their initial weights on 0 and 1 d (P < 0.05). Colonization, measured as C. jejuni plate count in fresh feces, also differed by variable antibiotic treatments (P < 0.0005). Subsequent post hoc TukeyÕs test indicated that fecal colonization after 3 and 7 d of antibiotic treatment differed from one another and from days 0 and 1 (P < 0.05) (Figure 2) . . The statistical evaluation of HEp-2 data is independent of the evaluation of HT-29 data, and they are shown together only to illustrate visual concordance of changes induced by the experimental variables. Within panels A and B, means without a common letter differ (P , 0.05); within panels C and D, asterisks (*) indicate differences between infected cells that were or were not treated with 2#-FL (P , 0.05). CXCL2, chemokine (C-X-C motif) ligand 2 (gene for MIP-2); CXCL8, chemokine (C-X-C motif) ligand 8 (gene for IL-8); DBA, Dolichos biflorus agglutinin; HK, heat-killed; HMOS, human milk oligosaccharide; LTL, Lotus tetragonolobus lectin; MIP-2, macrophage inflammatory protein-2; TNFA, tumor necrosis factor a; UEA-I, Ulex europaeus agglutinin I; 2#-FL, 2#-fucosyllactose.
2#-Fucosyllactose averts inflammation by C. jejuni 1983
Group 1 consisted of uninfected negative controls. Group 2 consisted of uninfected mice that received 5 g 2#-FL/L for 3 d, which were essentially similar to untreated controls in all variables measured. Group 3 consisted of positive controls infected by C. jejuni with no further intervention, which lost 9.8% of their initial (before antibiotic treatment) body weight after 3 d (P < 0.014; Figure 3A) , with a high DAI (P < 0.001; Figure 3B ), fecal shedding of C. jejuni (P < 0.001; Figure 3C ), and infection of the intestines, spleen, and MLNs (P < 0.0005; Figure 3C ) relative to groups 1 and 2 (uninfected negative controls). Group 4 was infected with a C. jejuni inoculum containing 2#-FL. Two-factor ANOVA indicated a significant interaction between 2#-FL treatment and C. jejuni infection for the following: body weight (P = 0.001) ( Figure 3A ), DAIs (P < 0.0005) ( Figure 3B ), shedding of fecal C. jejuni (P < 0.0005), infection of intestines (P < 0.0005), infection of spleen (P < 0.0005), and infection of MLNs (P < 0.0005) ( Figure 3C ). Mean comparisons with Bonferroni adjustment indicated that 2#-FL attenuated the weight loss associated with C. jejuni infection (P = 0.02) with infected, but treated, mice weighing within 1% of uninfected controls. The reduction of infection by 2#-FL is associated with attenuation of pathogen-induced p-38 activation in the colonic mucosa (Supplemental Figure 3B ). DAIs were reduced by 57% (Figure 3A , B; P < 0.0005), fecal shedding was reduced by ;90% (P < 0.005), infection of intestine reduced by 80% (P < 0.005), infection of spleen was reduced by 96% (P < 0.0005), and infection of MLNs was reduced by 93% (P < 0.0005; Figure 3C ). Group 5 received 2#-FL for 3 d before and concurrent with the 3 d of inoculation; the inoculum, as in group 4, contained both C. jejuni and 2#-FL. Two-factor ANOVA indicated a significant interaction between 2#-FL treatment and C. jejuni infection for the following: body weight (P < 0.005; Figure 3A ), DAIs (P < 0.0005; Figure 3B ), shedding of fecal C. jejuni (P < 0.0005), infection of intestines (P < 0.0005), infection of spleen (P < 0.0005), and infection of MLNs (P < 0.0005; Figure 3C ). Mean comparisons with Bonferroni adjustment indicated that 2#-FL attenuated the weight loss associated with C. jejuni infection (P = 0.02); infected but treated mouse weights were within 1% of uninfected controls. Relative to infected positive controls, treatment with 2#-FL reduced the DAIs by 77% (Figure 3A , B; P < 0.005), fecal shedding by 99% (P < 0.0005), infection of intestine by 97% (P < 0.0005), infection of spleen by 97% (P < 0.0005), and infection of MLNs by 98% (P < 0.0005; Figure 3C ).
Note that these biomarkers of C. jejuni-induced disease and inflammation were reduced by the 2#-FL treatment by such an extent that they were not significantly different from those of the negative controls. Thus, prophylactic treatment with 2#-FL added to the protection afforded by simultaneous treatment, offering almost complete protection.
Histology of mucosal injury. Histopathology of C. jejuniinfected mucosal sections of colonic mucosa showed extensive infiltration by immune cells, including neutrophils (P < 0.0005), epithelial ulceration (P < 0.0005), goblet cell depletion (P = 0.007), submucosal edema (P < 0.0005), and a histopathology score reflecting crypt hyperplasia with abscesses (P < 0.0005), reminiscent of the histopathology of human C. jejuni-infected mucosal colitis (Figure 4) . Mice whose inoculation was accompanied by 2#-FL exhibited attenuated mucosal colitis with some submucosal edema ( Figure 4C ), whereas pretreatment with 2#-FL before and during inoculation protected mucosa from C. jejuni-associated injury even more strongly than concurrent treatment alone, exhibiting no apparent mucosal colitis or injury relative to uninfected negative controls ( Figure 4D) . Two-factor ANOVA indicated a significant interaction between 2#-FL treatment and C. jejuni infection for the following: goblet cell depletion (P-interaction < 0.0005; Figure 4E ), histopathology score (P-interaction < 0.0005; Figure 4F ), myeloperoxidase 7 positive (MPO7) + neutrophil infiltration (P-interaction < 0.0005; Figure  4G ), and CD3 + lymphocyte infiltration (P-interaction < 0.0005; Figure 4H ). Mean comparisons with Bonferroni adjustment indicated that 2#-FL attenuated C. jejuni infection-mediated goblet cell depletion by 53% (P = 0.007), histopathology score by 72% (P < 0.0005), MPO7 + neutrophil infiltration by 47% (P < 0.0005), and CD3 + lymphocyte infiltration by 54% (P < 0.0005).
Mucosal inflammatory signaling. C. jejuni infection strongly induced mucosal secretion in mouse colons of NF-kB-dependent inflammatory mediators IL-1b (P < 0.0005), IL-6 (P < 0.0005), TNF-a (P = 0.006), and MIP-2 (P = 0.002) and their corresponding Il1b (P = 0.001), Il6 (P < 0.0005), Tnfa (P < 0.0005), and Cxcl2 (P < 0.0005) mRNAs ( Figure 5 ). Two-factor ANOVA indicated a significant interaction between 2#-FL treatment and C. jejuni infection for pathogen-induced expression in colonic mucosa of the following: IL-1b (P-interaction < 0.0005; Figure 5A ), IL-6 (P-interaction < 0.0005; Figure 5B ), TNF-a (P-interaction = 0.001; Figure 5C ), and MIP-2 (P-interaction < 0.0005; Figure 5D ) and their respective Il1b (P-interaction < 0.0005; Figure 5A ), Il6 (P-interaction < 0.0005; Figure 5B ), Tnfa (P-interaction < 0.0005; Figure 5C ), and Cxcl2 (P-interaction < 0.0005) mRNAs ( Figure 5D ). Mean comparisons with Bonferroni adjustment indicated significant attenuation by 2#-FL of C. jejuni induction of IL-1b protein by 51% (P < 0.0005; Figure 5A ), IL-6 by 78% (P < 0.0005; Figure 5C ), TNF-a by 37% (P = 0.006; Figure 5D ), and MIP-2 by 70% (P < 0.005; Figure 5D ) in the colon. Treatment with 2#-FL reduced Il1b mRNA expression by 65% (P < 0.005), Il6 mRNA by 53% (P < 0.0005), Tnfa mRNA by 31% (P = 0.006), and Cxcl2 mRNA by 40% (P < 0.0005, Figure 5 ). In the spleen (Figure 6 ), C. jejuni infection also induced Il1b, Il6, Tnfa, and Cxcl2 mRNAs (P < 0.0005 for all). Two-factor ANOVA indicated a significant interaction between 2#-FL treatment and C. jejuni infection for the induction of Il1b (Figure 6A ), Il6 ( Figure 6B ), Tnfa ( Figure 6C ), and Cxcl2 ( Figure 6D ) mRNAs in the spleen (P-interaction < 0.0005 for all). Mean comparisons with Bonferroni adjustment indicated significant attenuation by 2#-FL of C. jejuni for the expression of Il1b mRNA by 40% (Figure 6A ), Il6 mRNA by 53% (Figure 6B ), Tnfa mRNA by 42% ( Figure 6C ), and Cxcl2 mRNA by 58% ( Figure 6D ) in the spleen (P < 0.0005 for all).
Similarly, in MLNs (Figure 6 ), C. jejuni infection induced Il1b mRNA (P < 0.0005), Il6 mRNA (P < 0.0005), Tnfa mRNA (P = 0.035), and Cxcl2 mRNA (P < 0.0005). Two-factor ANOVA indicated a significant interaction between 2#-FL treatment and C. jejuni infection for the induction of Il1b mRNA ( Figure 6A ), Il6 mRNA ( Figure 6B ), Tnfa mRNA ( Figure 6C ), and Cxcl2 mRNA ( Figure 6D ) in the MLNs (P-interaction < 0.0005 for). Mean comparisons with Bonferroni adjustment indicated significant attenuation by 2#-FL of C. jejuni for the expression of Il1b mRNA by 25% (P < 0.05; Figure 6A ), Il6 mRNA by 44% (P < 0.0005; Figure 6B ), Tnfa mRNA by 31% (P = 0.035; Figure 6C ), and Cxcl2 mRNA by 61% (P < 0.0005; Figure 6D ) in the MLNs.
The adaptive response markers, IL-17 protein and Il17a mRNA, were not induced by C. jejuni infection nor influenced by 2#-FL treatment. Thus, in this acute infection model, C. jejuni infection activates the inflammasome and innate immune responses in the colonic mucosa but does not activate the adaptive response. Treatment with 2#-FL suppressed pathogen-mediated activation of both inflammasome and innate immune responses without altering the adaptive immune response in response to C. jejuni infection.
Discussion
The reduced risk of infectious disease by breastfeeding had been attributed primarily to secretory antibodies in human milk. HMOSs are now recognized as part of an innate immune system whereby the mother protects her infant (33) by 3 distinct activities: antiadhesive, prebiotic, and anti-inflammatory.
Although many HMOSs are fucosylated, the expression of specific fucosylated oligosaccharides in milk varies by maternal genotype. In breastfed infants, differences in milk content are strongly associated with the risk of infectious disease in the neonate (34) . A high content of 2#-FL is associated with a lower risk of C. jejuni infection. This is consistent with the finding that the intestinal mucosal receptor for C. jejuni contains a 1,2 -linked fucose and that 2#-FL inhibits C. jejuni binding (35) .
The binding specificity of C. jejuni varies by strain, and as with the related species Helicobacter pylori (36, 37), C. jejuni has broad binding specificity for mucins and other complex glycans (38, 39) . In glycan arrays, C. jejuni strain NCTC 11168 binding specificity varies according to growth conditions; under growth conditions mimicking mammalian and avian hosts, NCTC 11168 binds glycans terminating in a-and b-linked galactose and to fucosylated glycans. Mannose and sialic acid are required for initial binding to host tissues, but long-term infection requires fucose and terminal galactose moieties (15) . Lewis B and H-2 are the primary glycan moieties recognized (14) . Accordingly, high concentrations of L-fucose (39) , the fucose binding lectin UEA-I, and the galactose recognizing lectin Ricinus communis agglutinen I (RCA-I) inhibit adherence of C. jejuni strain NCTC 11168 to epithelial cells (15) .
Other strains of C. jejuni also depend on fucose for binding. Binding of a virulent clinical isolate, C. jejuni strain 287ip, to HEp-2 cells is inhibited by carbohydrate moieties containing fucosylated H-2 moieties (10). Strain 287ip binds to Chinese hamster ovary cells only when the cells are transfected with a human a 1,2 -fucosyltransferase gene that causes overexpression of H-2 antigen. This binding is inhibited by anti-H-2 monoclonal antibodies (block H-2) and by competitive inhibitors of H-2 binding, including 2#-FL. Pathogenic (invasive) strains of C. jejuni bind strongly and specifically to H-2 glycoconjugates, whereas adherent (nonpathogenic) strains do not (10) . Binding of strain 287ip to human intestinal mucosa ex vivo is inhibited by HMOSs or 2#-FL (10). Here, infection by C. jejuni of HT-29 and HEp-2 cells was inhibited by 2#-FL, fucose-specific lectins, and galactose-specific lectins, indicating that C. jejuni strain 81-176 binds fucose and that this binding is an essential first step of infection. This fastidious binding by C. jejuni to only specific host cell fucosylglycans is consistent with the paucity of nonhuman models of infection by human C. jejuni pathogens, such as ferrets (7) .
The use of modified murine models of C. jejuni colonization (8) (9) (10) (11) (12) is based on the importance of microbiota in the natural resistance of mice to human strains of C. jejuni. Previous murine models of C. jejuni infection used pretreatment with antibiotics. A single gavage of vancomycin 4 h before C. jejuni inoculation did not induce true infection in mice (12) . Conversely, treatment of mice with a cocktail of antibiotics for 6-8 wk before inoculation resulted in massive C. jejuni infection equally from the stomach to the colon, a degree of infection not seen in human patients (11) . To develop our model, varying times of treatment with a particular cocktail of antibiotics were tested for their ability to produce features that most resembled those of clinical C. jejuni infection; treatment for 7 d optimized infection and signaling. C. jejuni strain 81-176 consistently and robustly infected the intestinal mucosa, which exhibited extensive signs of colitis analogous to C. jejuni-associated colitis in humans. Inoculated mice were protected when 2#-FL feeding was simultaneous with the C. jejuni inoculation, and even more so when the treatment was initiated before inoculation. The protection before or with the inoculum, with no further protection post-treatment, suggests that part of the protection by 2#-FL involves restoration of the microbiota through a prebiotic mechanism. Prebiotics, indigestible dietary glycans that confer health benefits, increase diversity and numbers of intestinal microbiota. HMOSs, which are prebiotics, promote the colonization of the distal gut by mutualistic bacteria that selectively ferment HMOSs to produce organic acids, reduce ambient pH, and inhibit growth virulence of pathogens (40) . Such changes would reduce C. jejuni infection and mucosal inflammatory responses.
In vivo models integrate multiple phenomena, including those mediated by the microbiota, whereas human cell culture models reflect the response to C. jejuni infection per se. Elevated synthesis and release of IL-8 is a characteristic innate immune response of HECs to enteric infection (5, (41) (42) (43) (44) . A virulent strain of S. typhimurium (American Type Culture Collection 14028 wild-type), but not the attenuated strain sipA 2 , induces Il8 mRNA synthesis and p38 MAPK within 6 h of infection in intestinal epithelial cells. The inhibition of p38 kinases prevents this pathogen-induced IL-8 induction (45) . The data herein showed that C. jejuni infection also induced IL-6 and IL-8 synthesis and release from cultured HECs accompanied by induction of p38 kinases; these were abrogated by 2#-FL treatment. C. jejuni infection of mouse intestinal mucosa also elevated mRNA levels and protein release of IL-6, TNF-a, IL-1b, and MIP-2 and induced p38, and these changes were attenuated in 2#-FL-treated mice. The involvement of the p38 signaling pathway in C. jejuni infection, and attenuation of this pathway and its downstream proinflammatory mediators by 2#-FL, does not preclude the potential involvement of other signaling webs, such as those linked to protein kinase B (Akt), c-Jun N-terminal kinase (ERK), and c-Jun N-terminal kinase (JNK). The identification of other potential signaling pathways and putative cellular receptors for 2#-FL is of interest for future studies. The increase in IL-6 and TNF-a in mice was interpreted as an acute-phase response to pathogen infection, IL-1b as reflecting inflammasome activation, and MIP-2 as induction of a neutrophil chemoattractant gradient (44, 46) . In contrast to these innate immune responses, the lack of change in IL-17 concentrations suggested limited involvement by the adaptive immune response during the early phase of the immune response in this murine model of acute C. jejuni infection.
Treatment with 2#-FL attenuated the increase in overall mucosal response and inflammasome response elicited by C. jejuni infection, which is consistent with reduced C. jejuni infection in 2#-FL-treated mice. Not shown is an additional group fed 2#-FL after the inoculation for an additional 3 d, whose weight changes and DAIs were essentially similar to those whose 2#-FL treatment was only that contained in the inoculum. However, only prophylactic treatment of 2#-FL for the 3 d before infection significantly reduced MIP-2. This suggests a change in the microbiota community composition through a prebiotic FIGURE 5 (A-E) Colonic inflammatory markers in Campylobacter jejuni-infected C57BL/6 mice treated with 2#-fucosyllactose (Expt. 4). The induction of inflammatory mediator proteins and mRNAs by C. jejuni infection in the mouse colon, measured in media from organ culture, was suppressed by 2#-fucosyllactose. Values are means 6 SDs, n = 4 mice/group. Within the protein or mRNA data sets, means without a common letter differ (P , 0.05). Cj, pretreated with antibiotics and inoculated with C. jejuni; Cj+2#-FL, inoculated with C. jejuni with simultaneous 2#-fucosyllactose; Cont, control mice pretreated with antibiotics only; Cxcl2, chemokine (C-X-C motif) ligand 2 (gene for MIP-2); MIP-2, macrophage inflammatory protein 2; Tnfa, tumor necrosis factor a; 2#-FL, pretreated with antibiotics and 2#-fucosyllactose; 3d2#-FL-Cj+2#-FL, pretreated with 2#-fucosyllactose before inoculating with C. jejuni + 2#-fucosyllactose.
2#-Fucosyllactose averts inflammation by C. jejuni 1987 effect of 2#-FL, thereby influencing inter-kingdom communication between mutualistic bacteria and mammalian intestinal mucosa. Such communication would be through signaling pathways that are distinct from, but intersect with, pathways used for inflammatory signaling (25) . The data herein could be interpreted as 2#-FL exhibiting antiadhesive, prebiotic, and anti-inflammatory activities, but the experiments do not differentiate among these overlapping mechanisms of protection. Yet, the further protection afforded by 3 d of pretreatment with 2#-FL before inoculation, but not by 3 d of supplemental 2#-FL postinoculum (data not shown), strongly implicates an additional prebiotic effect as prophylactic to C. jejuni exposure. This modified murine model, wherein microbiota disruption preceded C. jejuni inoculation, recapitulated several known principal clinical responses to infection: acute transient enteric infection, immune response, and spontaneous clearing. This provides confidence in the potential clinical relevance of the inflammatory mechanisms of pathogenesis measured and their response to oral agents that protect against C. jejuni infection. Furthermore, because it is based on antibiotic pretreatment, this model is relevant to other human diseases associated with antibiotic use. This in vivo model, combined with the HEC in vitro models, confirmed the identification of 2#-FL as the HMOS most strongly associated with inhibition of C. jejuni. The inhibition by 2#-FL now shown for C. jejuni strain 81-176, yet another independent clinical isolate, further reinforces the conclusion that 2#-FL inhibits a common virulence factor critical for C. jejuni pathogenesis. Three putative mechanisms of 2#-FL inhibition are as follows: binding inhibition, which would diminish the ability of C. jejuni to infect; prebiotic activity, which would accelerate recovery of the microbiota disrupted by antibiotics, allowing the beneficial microbes to compete better with C. jejuni; and inhibition of inflammatory signaling. The confluence of in vitro and in vivo results supports binding inhibition and inhibition of inflammation (direct, indirect, or both); the efficacy of pretreatment by 2#-FL in vivo supports the prebiotic mechanism. These C. jejuni infection models could now be used to differentiate among these potential mechanisms of 2#-FL for each of these overlapping phenomena. Feeding pure 2#-FL may prove useful as a novel clinical prophylactic and therapeutic agent against C. jejuni and other enteric pathogens. the data and wrote the manuscript; and DSN had primary responsibility for the final content. All authors read and approved the final manuscript.
